Opioid addiction is recognized as a critical health care issue that has increased in recent years due to the advent and subsequent abuse of slow release opioids such as oxycodone ([@R1]; [@R12]; [@R18]). Across the province of Ontario (Canada), opioid use and subsequent addiction is seen as a major health crisis ([@R13]; [@R20]; [@R25], [@R26]). For example, [@R14] recently reported that approximately 12% of deaths in patients between the ages of 25 and 34 years occur due to opioid-related overdoes.

Despite the severity of opioid dependence in Ontario and a rapid expansion in access to treatment over the past 20 years, access to addiction therapy is not uniformly distributed across all regions of the province ([@R5]). Clinical practice guidelines state that methadone maintenance therapy (MMT) is the standard of care for treating patients with opioid dependence ([@R16]; [@R7]). Methadone maintenance therapy is a substitution/maintenance treatment model whereby the patient receives methadone in a structured treatment environment to reduce or eliminate the uncontrolled use of illicit opioids ([@R8]). With substance use disorders as a primary driver of opiate-related overdoses, expanding access to addiction treatment services is recognized to be an important goal of treatment programming and policy throughout North America and Europe ([@R36]).

In Ontario, patients receiving MMT will frequently commence treatment at a specialized addiction clinic where a nurse or pharmacist will observe medication intake on a daily basis during initial treatment, with the future possibility of treatment in a family physician\'s office or community pharmacy following stabilization ([@R3]; [@R3]). It is a noteworthy difference from the American mode such that, in Ontario, observed dosing can be administered at several types of approved locations including a family physician\'s office, addiction clinic, or local pharmacy. By contrast, the American model of directly observed therapy is considerably more restrictive only allowing methadone dosing to occur at regulated opioid treatment programs.

Best results for MMT, including reduced mortality rate and improved psychosocial function, are linked to continuous treatment, often over the course of several years or even decades, with gradual reduction in the level of observed medication ([@R16]; [@R32]; [@R3]; [@R29], [@R30], [@R31]; [@R10]; [@R35]). Maintenance treatment is fundamentally different from weaning strategies because patients may remain on methadone or buprenorphine for extended periods ([@R33]). A key element of treatment is that patients receive frequent and detailed care by an addiction-trained physician including urine drug screening, counseling, and general medical care ([@R16]).

In northern regions of Ontario, patients are subject to several barriers in accessing care. For example, northern patients may have difficulty enrolling in treatment due to the well-documented lack of primary care physicians, and they may also have to travel longer distances to reach a nurse or pharmacist prepared to provide observed dosing ([@R1]; [@R6]; [@R20]).

Currently, there is a gap in knowledge with respect to MMT retention and mortality rates for patients residing in differing geographies, especially where access to addiction services are markedly reduced. Here, we evaluate the relationship between location of residence and both treatment retention and mortality among first time MMT patients across Ontario, Canada.

METHODS
=======

Cohort Definition
-----------------

We conducted a retrospective cohort study of patients initiating MMT for the first time between January 1, 2003, and March 31, 2012, in the province of Ontario. First-time MMT therapy was defined as no previous history of methadone or buprenorphine use in the year before the first treatment episode. Although all patients started on methadone, we did include patients who transitioned to buprenorphine over the course of treatment. New starts on buprenorphine were excluded because of the small number of such treatment episodes within the time frame studied. All patients were at least 10 years or older (to exclude data entry errors for newborns; patients \<18 years accounted for \<1% of cohort) and were eligible for public drug coverage through the Ontario Drug Benefit (ODB) plan. Patients with less than 180 days of eligibility for public drug coverage before initiating MMT (as evidenced by no prescriptions for any drug in the 180 to 365 days before cohort entry) were excluded to avoid incomplete drug records. In Ontario, methadone used for addiction treatment is dispensed exclusively in liquid formulation (with very few exceptions). Therefore, patients prescribed methadone in a tablet formulation, with a medication possession ratio greater than 20% over a 1-year period, were excluded due to the likelihood that methadone was being administered for chronic pain management despite being coded for addiction therapy in the billing records. We also excluded patients with missing information regarding place of residence, age, or sex. All patients were followed from their date of MMT initiation to the date of treatment discontinuation (patient did not receive a prescribed dose of methadone or buprenorphine within 30 days of their last methadone or buprenorphine prescribed dose), death, 1-year follow-up, or end of the study period (March 31, 2013).

Data Sources
------------

The ODB database was used to identify all patients initiating MMT and to determine their past medication use. The ODB database contains detailed records of all prescriptions dispensed to Ontario residents eligible for public drug coverage. In Ontario, residents are eligible for public drug coverage if they are aged 65 years or older, reside in a long-term care facility, are disabled, are receiving social benefits for income support, or have high prescription drug costs relative to their net household income. Emergency department visits were identified using the Canadian Institute for Health Information National Ambulatory Care Reporting System, and hospital admissions were identified using the Canadian Institute for Health Information Discharge Abstract Database. All diagnosis information from physician visits was determined using billing data from the Ontario Health Insurance Plan database (Ontario Health Insurance Plan covers physician services for all permanent residents of Ontario). We obtained patient location of residence and demographic information from the Ontario Registered Persons Database, which contains a unique entry for each resident who has ever received insured health services. Patient information was linked anonymously across databases using encrypted 10-digit health card numbers. The linking protocol has been described extensively elsewhere ([@R22]; [@R15]), and it is used routinely for health system research in Ontario ([@R27]; [@R17]; [@R19]).

Geographic Definitions
----------------------

We used each patient\'s postal code to determine their location of residence at the outset of MMT. Provincially defined health regions (Local Health Integration Networks) were used to stratify patient location of residence into northern and southern regions. Local Health Integration Networks are regional health authorities who govern the administration of health service funding across defined geographic areas of Ontario. We distinguished rural from urban locations using the Rurality Index of Ontario (RIO) ([@R1]). The RIO metric is influenced by 3 weighted components---population density, travel time to nearest advanced referral center, and travel time to basic referral center. A region with a RIO of 40 or more was defined as rural on the basis of scoring system defined by the Ontario Medical Association ([@R21]). All patients were stratified into 1 of the following 4 geographic regions: Southern Urban, Southern Rural, Northern Urban, or Northern Rural.

Definition of Treatment Retention
---------------------------------

All patients were followed for at least 1 year, to a maximum follow-up date of March 31, 2013. Continuous MMT was assessed on the basis of a prescription refill within 30 days of the previous prescription (ie, no period of 30 consecutive days without a prescribed dose). We defined a patient as having been retained in treatment if they completed at least 1 year of continuous and uninterrupted MMT.

Definition of Mortality
-----------------------

All patients were followed for 1 year after MMT initiation to determine the all-cause mortality rate in each geographic region.

Statistical Analysis
--------------------

Descriptive statistics were summarized for baseline characteristics of patients, and standardized differences were used to compare characteristics between those residing in Southern Urban (locations to each of the other geographic regions). We chose the Southern Urban group as the reference group because it represents the majority of MMT delivered in the province of Ontario. Standardized differences less than 0.1 are generally not considered to be meaningful ([@R28]). For the primary analysis, we used logistic regression analysis to test the association between geographic location of residence and successful retention in MMT for at least 1 year, adjusting for patient covariates that were imbalanced between geographic regions. Covariates included age, sex, income quintile, Charlson score, prior prescription of benzodiazepine stimulant or antidepressant, the number of hospitalizations, the number of physician visits, the number of emergency department visits, and the number of prescribed drugs. We used the Kaplan-Meier method to characterize the time to discontinuation across the 4 groups. For the secondary analysis, we used logistic regression analysis to test the association between geographic location of residence and all-cause mortality within 1 year of treatment initiation, adjusting for the patient covariates that were imbalanced between geographic regions.

Ethics Review
-------------

This study was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre, Toronto, Ontario, and the Research Ethics Board of Laurentian University, Sudbury, Ontario.

RESULTS
=======

Over the study period, we identified 17,211 publicly funded eligible patients who commenced MMT. Of these, 14,052 (81.7%) resided in a Southern Urban region, 1,011 (5.9%) in a Southern Rural region, 1,620 (9.4%) in a Northern Urban region, and 528 (3.1%) in a Northern Rural region of the province.

Characteristics of patients initiating MMT did not differ substantially by age or sex based on location of residence (Table [1](#T1){ref-type="table"}). However, individuals initiating MMT in northern regions were more likely to have previously received prescriptions for benzodiazepines, stimulants, and antidepressants compared with those residing in Southern Urban regions. There were no significant differences between Southern Rural and Southern Urban patients with respect to these classes of prescriptions. Patients in northern regions also had more emergency department and hospital visits but had fewer physician visits overall. Patients residing in Northern Rural locations resided much farther from their addiction care provider (median distance = 127 km; interquartile range = 52--287 km) compared with patients residing in Southern Urban regions (median distance = 16 km, interquartile range = 4--52 km).

Nearly half of patients initiating MMT in northern regions successfully completed 1 year of continuous treatment (48.9%; N = 258 and 47.0%; N = 761 in Northern Rural and Urban regions, respectively). In comparison, in Southern Rural and Urban regions, only 40.6% (N = 410) and 39.3% (N = 5,518) successfully completed 1 year of treatment. After multivariate adjustment, patients residing in Northern Rural regions were 31% more likely to successfully be retained in MMT for at least 1 year compared with those residing in Southern Urban regions (adjusted odds ratio \[aOR\] = 1.31; 95% confidence interval \[CI\], 1.09%--1.58%). Similarly, those residing in Northern Urban regions were 14% more likely to successfully be retained in treatment for at least 1 year (aOR = 1.14; 95% CI, 1.02%--1.27%) compared with those residing in Southern Urban regions. There was no statistically significant difference in the likelihood of successful retention in MMT between those initiating therapy in Southern Rural and Southern Urban locations (aOR = 1.06; 95% CI, 0.92%--1.22%). The time to discontinuation of MMT differed significantly by geographic region over follow-up (Fig. [1](#F1){ref-type="fig"}; *P* \< 0.001). In particular, the median time to discontinuation was shortest in Southern Urban regions (188 days) and longest in Northern Rural regions (351 days).
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To identify if geographic status may also contribute to risk of mortality, we examined all-cause mortality rates within 1 year of a patient initiating MMT. Of the 17,211 patients initiating MMT, 585 deaths were observed within 1 year of date of initiation; of which, 140 deaths occurred while the patients were actively enrolled in treatment and 445 occurred in patients who had discontinued MMT (ie, \>30 days following most recent methadone prescription). Methadone maintenance therapy patients in the Southern Rural region of the province demonstrated a mortality rate of 4.85% as compared to 3.38% for patients from the Southern Urban reference group. After adjusting for age, sex, income quintile, Charlson score, prior prescription of benzodiazepine, stimulant or antidepressant, the number of hospitalizations, the number of physician visits, the number of emergency department visits, and the number of prescribed drugs, patients in the Southern Rural region of the province had a 54% (aOR = 1.54; 95% CI, 1.09%--2.17%) increased likelihood of mortality within 1 year of initiating MMT as compared to the Southern Urban reference group. Comparatively, Northern Urban and Northern Rural patients were not as pronounced a difference as compared to the reference group (Table [2](#T2){ref-type="table"}).

DISCUSSION
==========

Our primary finding highlights that northern geographic status is associated with improved treatment retention in first-time MMT patients in the province of Ontario, Canada. Both rural and urban regions of Northern Ontario have well-documented geographic characteristics, which contribute to reduced access to care and limited health human resources ([@R1]; [@R6]; [@R20]). Methadone maintenance therapy is a treatment strategy that centers initially on the observed dosing of methadone or buprenorphine under the medical supervision of an addiction specialist. In Ontario, there is a requirement for patients to present to an addiction treatment center or pharmacy for observed dosing during the initial period of therapy. In Northern Ontario, the need to travel can pose a barrier to accessing treatment, due to the considerable distance a patient may be required to travel to reach the site of observed dosing or the longer lead-time required to access care ([@R6]; [@R20]). We demonstrate that patients in Northern Urban and Rural regions of Ontario have a higher likelihood of successful treatment retention despite having to overcome barriers to care, including geography. Interpreted more generally, our data suggest that increased barriers to therapy may contribute to higher treatment retention for first-time MMT patients. It is very common for MMT patients to reinitiate treatment multiple times before they are stabilized ([@R29]). Thus, we suggest that our finding should be interpreted in the context of the relationship which exists between the patient and program accessibility, treatment retention, and treatment re-entry.

The primary finding was counter to our initial hypothesis. In the case of MMT, residence in Northern regions improved the likelihood of positive treatment retention for first-time MMT patients. This is somewhat surprising because our findings suggest that Northern Rural patients were required to travel much further to access therapy as compared to urban counterparts. It should be noted that patients in Ontario are able to receive daily supervised dosing at local pharmacies, and they are only required to see their prescribing physician 1 to 4 times per month. Thus, it is not uncommon for Northern patients to be physically removed from their physician by several hundred kilometers, but the patient would only be required to travel to the clinic for physician visits or urine testing once or twice per week while receiving observed daily doses at the pharmacy. Conversely, Southern Urban patients have considerably shorter distances to travel, and thus have a lower barrier to access care.

Considering the importance that a patient\'s self-motivation is recognized to play in addiction therapy ([@R23]), our findings can be reconciled under the presumption that the effort required to access care by northern patients selects for patients who do access therapy having a higher motivation for treatment. This may account for the improved retention rates reported here. A supporting phenomenon was reported in a longitudinal study performed during the expansion of MMT in Australia by [@R3]. These authors followed MMT retention as addiction therapy programming was developed and expanded in the state of New South Wales from 1990 to 2005. Importantly, [@R3] reported that as the access to the methadone program increased, treatment retention declined and patient cycling between therapy discontinuation and subsequent reinitiation became more frequent. Thus, it may follow that the greater ease of entry into addiction services in Southern regions of Ontario may contribute to lower retention rates observed for these patient groups. Interestingly, [@R34] conducted a similar analysis of MMT treatment retention earlier in the expansion of MMT across the province of Ontario, although using a different data source. In a cohort of approximately 10,000 patients from 1996 to 2001, these authors reported a retention of approximately 50% after 760 days of treatment ([@R34]). Our data indicate that retention rates have fallen to approximately 25% at this time point in the following decade (2003--2012). This observed difference in treatment retention, following Ontario MMT program expansion in the 2000 s, further supports the finding that lower first-time retention rates can be rationalized as access to addiction therapy become more widely available and barriers to access treatment decrease.

With respect to the Southern group of patients, several factors have been reported which may help to improve patient retention in the Southern regions of the province. For example, higher methadone dose ([@R4]; [@R9]), patient treatment satisfaction, access to stable housing, access to social programming, employment opportunities, and reduced access to nonprescribed (illicit) drugs all contribute to improved retention ([@R24]). Furthermore, patients in Northern and rural regions may also benefit from social constructs such as community support and increased access to affordable housing. Because of the nature of the data set utilized for this study, we are unable to specifically test the contributions of each of these factors, but it is important to recognize that there are many clinical, social, and systemic factors which influence the efficacy of MMT.

In addition to [@R3], congruent findings of MMT retention rates have been reported in the Ukraine. Importantly, the Ukraine is a jurisdiction with relatively limited opioid agonist therapy programming. Bachireddy et al. (2014) report that in a study group of 296 patients who were HIV-positive and opioid dependent, the median treatment retention in opioid substitution therapy was 31 months. Although not directly comparable with our study, the authors also reported that patients enrolled in opioid agonist therapy also experienced improved health-related quality of life ([@R2]). Findings demonstrating improved quality of care and health in areas where treatment options are limited underscore the importance of broadening access to opioid agonist therapy in jurisdictions that have limited treatment options such as Northern Ontario.

Secondary analysis of mortality for patients initiating MMT is an important metric in light of a recent study by [@R14], which demonstrated that in 2010, 12.1% of deaths in adults between the ages of 25 and 34 years can be attributed to an opioid-related overdose in the province of Ontario. We find that the number of deaths within 1 year for the patient population initiating MMT to be relatively low (3%) in the context of opioid-related deaths reported in the general population ([@R11]; [@R14]). Moreover, it should be highlighted that the majority of deaths (76%) in the study group occurred in patients who were not retained in the first treatment episode. Increased mortality rate in the Southern Rural group indicates that contributing factors such as increased distance to tertiary care center could account for this increased probability of death.

Our study has many strengths and limitations that warrant discussion. Using a health systems data approach over a 10-year study period, we were able to use robust statistical methods to characterize the effect of geography on MMT treatment retention in a cohort of patients with opioid addiction. Our analysis strategy enabled us to evaluate a critical aspect of addiction care that cannot be easily addressed by studying localized rates in large urban center programs or in a homogeneous clinical setting. However, we were unable to assess other societal factors that may influence treatment retention, such as access to and use of illicit drugs, employment opportunities, the stability of housing, or familial and community support. Further limitations to the health systems data approach include the potential for patients to lose eligibility for public drug coverage over follow-up (eg, as a result of becoming employed). In such cases, patients could seem to have discontinued therapy when they had instead changed coverage from public to private health-insurer. However, we do not believe that such cases would have a substantial impact on the data because they are likely to be rare in the first year of treatment and are unlikely to differ significantly by geography in a way that favors Northern or rural areas. As patients with incomplete health system profiles were excluded from analysis, patients accessing services outside the provincial health care funding would have fallen outside the scope of analysis (eg, undocumented immigrants). Because of the nature of the data and the time frame studied, we were also unable to assess the impact of telehealth-delivered MMT, which is recognized to be a treatment modality that has become more commonplace in rural and remote regions of Ontario (unpublished observation).

Our findings suggest that patients initiating MMT in northern regions have a greater likelihood of a successful treatment outcome as compared to those in Southern regions of Ontario when enrolling in MMT for the first time. The specific differences in patient factors (eg, availability of heroin vs prescription opioids, frequency of other illicit drug use, mental health issues, homelessness, and familial and community support) and program factors (reliance on telehealth, prescribing practices, ease of accessibility, etc), which may explain this difference, and the underlying explanation for excess mortality in the Southern Rural group, require further study.

Ultimately, understanding the barriers and facilitators to successful MMT offers the potential for improved treatment systems in all locations. Finding the proper balance between the patient, program accessibility, and program retention should be considered by those responsible for delivering and evaluating addiction therapy.
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###### 

Characteristics of Geographic Patient Groups

  Variable                                                      Southern Urban   Southern Rural                                    Northern Urban                                   Northern Rural
  ------------------------------------------------------------- ---------------- ------------------------------------------------- ------------------------------------------------ --------------------------------------------------
  Age, yr                                                                                                                                                                           
   Median (IQR)                                                 39 (29--52)      37 (28--52)                                       35 (27--45)[^\*^](#TF1-1){ref-type="table-fn"}   36 (27--47)[^\*^](#TF1-1){ref-type="table-fn"}
  Sex                                                                                                                                                                               
   Male                                                         7,063 (50.3%)    498 (49.3%)                                       720 (44.4%)[^\*^](#TF1-1){ref-type="table-fn"}   244 (46.2%)
  Charlson score                                                                                                                                                                    
   No hospitalizations                                          8,529 (60.7%)    581 (57.5%)                                       854 (52.7%)[^\*^](#TF1-1){ref-type="table-fn"}   261 (49.4%)[^\*^](#TF1-1){ref-type="table-fn"}
   0                                                            3,714 (26.4%)    288 (28.5%)                                       560 (34.6%)[^\*^](#TF1-1){ref-type="table-fn"}   201 (38.1%)[^\*^](#TF1-1){ref-type="table-fn"}
   1                                                            836 (5.9%)       60 (5.9%)                                         96 (5.9%)                                        25 (4.7%)
   2+                                                           973 (6.9%)       82 (8.1%)                                         110 (6.8%)                                       41 (7.8%)
  Prior prescribed medications (180 days before cohort entry)                                                                                                                       
   Opioids                                                      7,923 (56.4%)    580 (57.4%)                                       884 (54.6%)                                      305 (57.8%)
   Benzodiazepines                                              5,440 (38.7%)    366 (36.2%)                                       694 (42.8%)                                      237 (44.9%)[^\*^](#TF1-1){ref-type="table-fn"}
   Stimulants                                                   394 (2.8%)       27 (2.7%)                                         88 (5.4%)[^\*^](#TF1-1){ref-type="table-fn"}     26 (4.9%)[^\*^](#TF1-1){ref-type="table-fn"}
   Cannabinoids                                                 225 (1.6%)       16 (1.6%)                                         9 (0.6%)                                         ≤5
   Barbiturates                                                 17 (0.1%)        ≤5                                                ≤5                                               ≤5
   Antidepressants                                              5,953 (42.4%)    463 (45.8%)                                       724 (44.7%)                                      256 (48.5%)[^\*^](#TF1-1){ref-type="table-fn"}
   Antipsychotics                                               2,497 (17.8%)    158 (15.6%)                                       282 (17.4%)                                      109 (20.6%)
  Health system use (1 year before cohort entry)                                                                                                                                    
   No hospitalizations (mean ± SD)                              0.33 ± 0.86      0.38 ± 1.01                                       0.43 ± 1.03[^\*^](#TF1-1){ref-type="table-fn"}   0.47 ± 1.01[^\*^](#TF1-1){ref-type="table-fn"}
   No physician visits                                                                                                                                                              
    Median (IQR)                                                21 (11--37)      21 (11--35)                                       19 (10--33)[^\*^](#TF1-1){ref-type="table-fn"}   17 (10--29)[^\*^](#TF1-1){ref-type="table-fn"}
   No ED visits                                                                                                                                                                     
    Median (IQR)                                                1 (0--4)         2 (0--5)[^\*^](#TF1-1){ref-type="table-fn"}       2 (0--4)                                         4 (1--8)[^\*^](#TF1-1){ref-type="table-fn"}
   No drugs                                                                                                                                                                         
    Median (IQR)                                                10 (5--16)       9 (5--15)[^\*^](#TF1-1){ref-type="table-fn"}      9 (4--15)[^\*^](#TF1-1){ref-type="table-fn"}     9 (5--14)[^\*^](#TF1-1){ref-type="table-fn"}
   Distance to care provider (km)                                                                                                                                                   
    Median (IQR)                                                16 (4--52)       91 (34--159)[^\*^](#TF1-1){ref-type="table-fn"}   9 (3--320)[^\*^](#TF1-1){ref-type="table-fn"}    127 (52--287)[^\*^](#TF1-1){ref-type="table-fn"}

^\*^Indicates standardized difference \>0.10 when performing pair-wise comparison with Southern Urban group.

ED, emergency department; IQR, interquartile range; SD, standard deviation.

###### 

Treatment Retention at 1 Year and Mortality Rates During Course of First MMT Episode

  Region                                                                                              No Patients, N   No Outcomes, N(%)   Unadjusted OR   Unadjusted 95% CI   Adjusted OR[^\*^](#TF2-1){ref-type="table-fn"}   Adjusted 95% CI
  --------------------------------------------------------------------------------------------------- ---------------- ------------------- --------------- ------------------- ------------------------------------------------ -----------------
  Primary outcome: MMT retention at 1 y                                                                                                                                                                                         
  Southern Urban (reference group)                                                                    14,052           5,518 (39.3)        1                                   1                                                
  Southern Rural                                                                                      1,011            410 (40.6)          1.06            (0.93, 1.20)        1.06                                             (0.92, 1.22)
  Northern Urban                                                                                      1,620            761 (47.0)          1.37            (1.24, 1.52)        1.14                                             (1.02, 1.27)
  Northern Rural                                                                                      528              258 (48.9)          1.48            (1.24, 1.76)        1.31                                             (1.09, 1.58)
  Secondary outcome: risk of death for all patients within 1 y of initiating MMT by geographic area                                                                                                                             
  Southern Urban (reference group)                                                                    14,052           475 (3.38)          1                                   1                                                
  Southern Rural                                                                                      1,011            49 (4.85)           1.46            (1.08, 1.97)        1.54                                             (1.09, 2.17)
  Northern Urban                                                                                      1,620            45 (2.78)           0.82            (0.60, 1.11)        1.16                                             (0.82, 1.64)
  Northern Rural                                                                                      528              16 (3.03)           0.89            (0.54, 1.48)        1.03                                             (0.59, 1.81)

^\*^Adjusted for age, sex, income quintile, Charlson score, prior prescription of benzodiazepine stimulant or antidepressant, the number of hospitalizations, the number of physician visits, the number of emergency department visits, and the number of prescribed drugs.

CI, confidence interval; MMT, methadone maintenance therapy; OR, odds ratio.
